Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Lineage Cell Therapeutics's gross margin for the twelve months ending Mar 31, 2025 was 97.2%. For fiscal 2024 it was 96.5%, against 92.5% the year before. The highest annual figure on record is 99.3% in fiscal 2010.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 96.5% | +4.0 |
| FY2023 | Dec 31, 2023 | 92.5% | −2.6 |
| FY2022 | Dec 31, 2022 | 95.0% | +27.9 |
| FY2021 | Dec 31, 2021 | 67.2% | −11.8 |
| FY2020 | Dec 31, 2020 | 78.9% | −9.4 |
| FY2019 | Dec 31, 2019 | 88.3% | −5.7 |
| FY2018 | Dec 31, 2018 | 93.9% | −1.2 |
| FY2017 | Dec 31, 2017 | 95.1% | +1.2 |
| FY2016 | Dec 31, 2016 | 94.0% | +9.7 |
| FY2015 | Dec 31, 2015 | 84.3% | +0.2 |
| FY2014 | Dec 31, 2014 | 84.0% | +1.9 |
| FY2013 | Dec 31, 2013 | 82.1% | −6.8 |
| FY2012 | Dec 31, 2012 | 88.9% | −9.3 |
| FY2011 | Dec 31, 2011 | 98.2% | −1.0 |
| FY2010 | Dec 31, 2010 | 99.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | 97.6% | +4.4 |
| Q4 FY2024 | Dec 31, 2024 | 94.6% | +6.9 |
| Q3 FY2024 | Sep 30, 2024 | 99.0% | +12.6 |
| Q2 FY2024 | Jun 30, 2024 | 96.9% | +0.8 |
| Q1 FY2024 | Mar 31, 2024 | 93.2% | −1.8 |
| Q4 FY2023 | Dec 31, 2023 | 87.7% | −6.9 |
| Q3 FY2023 | Sep 30, 2023 | 86.4% | −5.7 |
| Q2 FY2023 | Jun 30, 2023 | 96.1% | +0.8 |
| Q1 FY2023 | Mar 31, 2023 | 95.0% | −1.6 |
| Q4 FY2022 | Dec 31, 2022 | 94.7% | +12.1 |
| Q3 FY2022 | Sep 30, 2022 | 92.2% | +35.6 |
| Q2 FY2022 | Jun 30, 2022 | 95.3% | +19.7 |
| Q1 FY2022 | Mar 31, 2022 | 96.6% | +25.3 |
| Q4 FY2021 | Dec 31, 2021 | 82.5% | +14.6 |
| Q3 FY2021 | Sep 30, 2021 | 56.6% | −25.5 |
| Q2 FY2021 | Jun 30, 2021 | 75.6% | −5.0 |
| Q1 FY2021 | Mar 31, 2021 | 71.4% | −10.4 |
| Q4 FY2020 | Dec 31, 2020 | 67.9% | −22.2 |
| Q3 FY2020 | Sep 30, 2020 | 82.1% | +2.2 |
| Q2 FY2020 | Jun 30, 2020 | 80.6% | −5.7 |
| Q1 FY2020 | Mar 31, 2020 | 81.7% | −11.0 |
| Q4 FY2019 | Dec 31, 2019 | 90.1% | −3.1 |
| Q3 FY2019 | Sep 30, 2019 | 79.9% | −16.5 |
| Q2 FY2019 | Jun 30, 2019 | 86.3% | −9.6 |
| Q1 FY2019 | Mar 31, 2019 | 92.7% | +8.2 |
| Q4 FY2018 | Dec 31, 2018 | 93.1% | −6.9 |
| Q3 FY2018 | Sep 30, 2018 | 96.4% | −3.6 |
| Q2 FY2018 | Jun 30, 2018 | 95.8% | −4.2 |
| Q1 FY2018 | Mar 31, 2018 | 84.5% | −15.5 |
| Q4 FY2017 | Dec 31, 2017 | 100.0% | +0.0 |
| Q3 FY2017 | Sep 30, 2017 | 100.0% | +0.0 |
| Q2 FY2017 | Jun 30, 2017 | 100.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 100.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 100.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 100.0% | – |
See a number that looks wrong?